Ace Therapeutics is an expert in the field of liver disease. With our extensive hands-on experience, we aim to provide a one-stop research platform for liver disease researchers.
Studies have shown that epidermal growth factor (EGFR) plays an important role in liver regeneration after acute, chronic liver injury, cirrhosis, hepatocellular carcinoma, and other liver diseases. This suggests that EGFR is a potential therapeutic target for liver disease. Therefore, we provide comprehensive research services in the field of developing liver disease drugs targeting EGFR to support the research projects of relevant investigators.
What Can We Do?
Based on our professional scientists and well-established research platform, we are committed to providing you with the most advanced and scientific drug development services for liver disease targeting EGFR.
- Small Molecule Modulators Screening Targeting EGFR
EGFR has an important role in maintaining liver function, but overexpression of EGFR can lead to tumorigenesis. Therefore, when developing EGFR small molecule modulators, we need to conduct disease-specific drug development studies accordingly.
- We will develop EGFR modulators for EGFR targets.
- We will develop EGFR modulators for different ligands of EGFR.
- We will provide different liver disease models to validate the function of the candidate modulators.
- We will examine key changes in hepatocyte activity, hepatic DNA synthesis, and matrix metallopeptidases based on the different activities of EGFR modulators.
- Small Molecule Inhibitors Screening Targeting EGFR
The EGFR system plays an important role in acute and chronic liver disease, and targeting small molecule inhibitors of EGFR can effectively inhibit the ongoing progression of liver disease. Therefore, we offer comprehensive drug development services for small molecule inhibitors of EGFR.
- We will examine the effect of EGFR inhibitor action on the expression of inflammatory factors in liver disease by gene level and protein level-based assays.
- We will quantify the changes in liver injury and the expression levels of biomarkers following the action of EGFR inhibitors by biochemical assays, ELISA, pathological assays, and mRNA assays.
- We will detect the effect of EGFR inhibitors on hepatitis virus by mRNA technique, ELISA, and western blotting.
- Development of Anti-EGFR Antibodies Targeting EGFR
Anti-EGFR antibodies have an important role in the treatment of liver diseases, especially liver cancer, and are currently a popular direction of research. We provide comprehensive services for the development of anti-EGFR antibodies.
- We have a comprehensive antibody development platform, including but not limited to hybridoma platform, phage display platform, bispecific antibody development platform, and antibody drug coupling platform.
- We will provide targeted antibody development and evaluation services for EGFR characteristics.
- We can provide humanization services for EGFR-specific antibodies as well as fully human antibody development services against EGFR.
Ace Therapeutics has a team of professionals in the field of developing targeted drugs for the treatment of liver diseases. We have extensive hands-on experience to provide you with high-quality data and a fast turnaround time to support the development of gut microbial drugs. If you would like to learn more about our services, please feel free to contact us.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
